cat no | io6015
Cryopreserved human iPSC-derived cells powered by opti-ox, that are ready for experiments in days
Built to investigate the impact of P2RY12 knockout for neuroinflammation research
Consistently perform key phagocytic and cytokine secretion functions, and are co-culture compatible
Human iPSC-derived microglia for neuroinflammation research
Phagocytosis of ioMicroglia P2RY12null/wt is demonstrated comparably to the WT control and ioMicroglia P2RY12null/null
Phagocytosis was analysed at day 10 post-revival after incubation with 1 µg/0.33 cm2 pHrodo RED labelled E. coli particles for 24 hours +/- cytochalasin D control. The graph displays the proportion of cells phagocytosing E.coli over 24 hours. ioMicroglia P2RY12null/wt cells display a similar proportion of phagocytosis compared to the ioMicroglia P2RY12null/null and WT control. Images were acquired every 30 mins on the Incucyte® looking at red fluorescence and phase contrast. Three technical replicates were performed experiment.
Key cytokine secretion function displayed by ioMicroglia P2RY12 null/wt
Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that ioMicroglia P2RY12null/wt cells display a similar level of cytokine secretion compared to the ioMicroglia P2RY12null/null and WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit. Three technical replicates were performed per experiment.
ioMicroglia P2RY12 null/wt express IBA1 comparably to the genetically matched wild-type control
Immunofluorescent staining on day 10 post-revival demonstrates similar homogenous expression of the microglia marker IBA1 and ramified morphology in ioMicroglia P2RY12 null/wt cells compared to the genetically matched wild-type control, ioMicroglia Male. 100X magnification.
ioMicroglia P2RY12 null/wt show expected ramified morphology by day 10
ioMicroglia P2RY12null/wt cells mature rapidly and key ramified morphology can be identified by day 4 and continues through to day 10, similarly to the WT control. Day 1 to 10 post-thawing; 100x magnification.
P2RY12null/wt heterozygous knockout confirmed by flow cytometry analysis
Flow cytometry analysis of ioMicroglia P2RY12null/wt demonstrates heterozygous knockout of the P2RY12 gene translating to the protein level. Microglia purity demonstrated by >95% expression of CD45, CD11b and CD14 expression.
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
ioMicroglia P2RY12 null/WT are opti-ox deterministically programmed microglia engineered as a heterozygous knockout of the P2RY12 gene. P2RY12 is a purinergic receptor that plays essential roles in microglia motility and migration, and is critical for initiating microglial responses to inflammation and damage.
These cells offer a functional, rapidly maturing model to study the role of P2RY12 in neuroinflammation research, alongside a genetically matched wild-type control.
Two clones are available on request, all genetically matched to the wild type control, ioMicroglia Male. The knockout model cells and the wild-type control offer a physiologically relevant model to investigate the effect of P2RY12 on microglia cellular and molecular mechanisms.
Making True Comparisons
Pair with the homozygous knockout and the genetically matched wild-type ioMicroglia to directly investigate the effect of P2RY12.
Quick
Rapidly maturing cells that are ready to use in 4 days post-revival, in mono- and co-cultures.
Functional
Display key phagocytic and cytokine secretion functions.
ioMicroglia P2RY12 null/WT are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: an Induction phase that is carried out at bit.bio, Phase 1: Stabilisation for 24 hours, Phase 2: Maturation for a further 9 days, Phase 3: the Maintenance phase. ioMicroglia are ready to use from day 4* for the key assays phagocytosis and cytokine secretion, day 10 is recommended for full maturation.
*Recommendations based on data from ioMicroglia Male WT.
Starting material
Human iPSC line
Seeding compatibility
6, 12, 24, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast),
Genotype APOE 3/3
Vial size
Small: >1.5 x 10⁶ viable cells, Evaluation pack*: 3 small vials of >1.5 x 10⁶ viable cells
Quality control
Sterility, protein expression (ICC), and functional phagocytosis
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
40,000 to 80,000 cells/cm²
User storage
LN2 or -150°C
Format
Cryopreserved cells
Product use
ioCells are for research use only
Genetic modification
Heterozygous knockout mutation in the P2RY12 gene
Applications
Drug discovery and development
Neuroinflammation modelling
Phagocytosis assays
cytokine response assays
Co-culture studies
Available clones
io6015S: ioMicroglia P2RY12 null/wt (clone 747P1D1)
io6014S: ioMicroglia P2RY12 null/wt (clone 747P1C1)
* Evaluation packs are intended for first-time users, or for existing users testing a new cell type or derivative. A user can request multiple evaluation packs as long as each one is for a different product, with only one pack allowed per product.
ioMicroglia P2RY12 null/WT show expected ramified morphology by day 10
ioMicroglia P2RY12 null/WT cells mature rapidly and key ramified morphology can be identified by day 4 and continues through to day 10, similarly to the WT control. Day 1 to 10 post-thawing; 100x magnification.
Key cytokine secretion function displayed by ioMicroglia P2RY12 null/WT
Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that ioMicroglia P2RY12 null/WT cells display a similar level of cytokine secretion compared to the ioMicroglia P2RY12 null/null and WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit. Three technical replicates were performed per experiment.
Key cytokine secretion function displayed by ioMicroglia P2RY12 null/WT
Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that iioMicroglia P2RY12 null/WT cells display a similar level of cytokine secretion compared to the ioMicroglia P2RY12 null/null and WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit. Three technical replicates were performed per experiment.
In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioMicroglia.
Euan Yates | Scientist | bit.bio
Human Cell Forum 2025
Session 2 | bit.bio insider: Tools, tips, and what’s coming next
Antonella Santuccione Chadha, MD | Founder and CEO | Women’s Brain Foundation
Melanie Einsiedler, PhD | Scientific Contributor | Women’s Brain Foundation
Rebecca Northeast, PhD | Senior Product Manager | bit.bio
V8
bit.bio
2025
In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.
Human iPSC-derived microglia engineered to constitutively express GFP enable easy visualisation, tracking and isolation of cells in complex multi-cell cultures.
Discover the data
Access 20 neuronal disease models and 4 microglia disease models with a single co-culture protocol.
View the co-culture protocol
Explore ioGlutamatergic Neuron Disease Models
Explore ioMicroglia Disease Models
Women are greatly underrepresented in drug development and clinical trials.
Introducing female-derived cells into the early stage of research and drug discovery can help to better address this disparity.
Key applications for Female ioMicroglia in neurodegeneration drug discovery
- Neuroinflammatory in vitro modelling
- Target ID and validation
- Compound screening
Discover the data
Built from our ioMicroglia Male and engineered to constitutively express Cas9.
With optimised guide RNA delivery protocols and high knockout efficiency, start measuring readouts from gene knockouts and CRISPR screens within days.
Save months of work by skipping complex cell line engineering and cell differentiation workflows.
Discover the data
Consistent. Defined. Scalable.